AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16931161 — intervention group
Group type: COMPARATOR
Intervention: Control group - instructed on a home-based exercise regimen without contact during the 8 weeks.
Number of subjects: 60
Study 16140624 — intervention group
Group type: EXPERIMENTAL
Intervention: Test substances (glue, body wash solution, dryer sheet)
Number of subjects: 17
Study 16140624 — intervention group
Group type: EXPERIMENTAL
Intervention: Body wash solution
Number of subjects: 17
Study 16140624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dryer sheets
Number of subjects: 17
Study 16140624 — intervention group
Group type: COMPARATOR
Intervention: Control substances (unscented shampoo and clean air)
Number of subjects: 17
Study 12125902 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured psychoeducational intervention program
Number of subjects: 0
Study 12125902 — intervention group
Group type: COMPARATOR
Intervention: Control ward
Number of subjects: 0
Study 10340202 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual pre-test counselling
Number of subjects: 3958
Study 10340202 — intervention group
Group type: COMPARATOR
Intervention: Group pre-test counselling
Number of subjects: 3958
Study 8712125 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (400 mg, oral administration for 90 minutes)
Number of subjects: 20
Study 8712125 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (0.3 mg, sublingual)
Number of subjects: 20
Study 1763646 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine dihydrochloride
Number of subjects: 55
Study 1763646 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 55
Study 7077550 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement
Number of subjects: 0
Study 7077550 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement plus positive expectancy
Number of subjects: 0
Study 7077550 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement plus negative expectancy
Number of subjects: 0
Study 7077550 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert positive reinforcement of pain
Number of subjects: 0
Study 7077550 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo
Number of subjects: 0
Study 7077550 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 31730554 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial prescription of 30 hydrocodone/acetaminophen pills (5/325 mg)
Number of subjects: 200
Study 31730554 — intervention group
Group type: COMPARATOR
Intervention: Initial prescription of 10 hydrocodone/acetaminophen pills (5/325 mg)
Number of subjects: 200
Study 27101805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20‐mg (on‐demand)
Number of subjects: 383
Study 27101805 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 100‐mg (on‐demand)
Number of subjects: 383
Study 26226090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) with routine primary care; 12 weekly 50-min sessions
Number of subjects: 66
Study 26226090 — intervention group
Group type: COMPARATOR
Intervention: Routine Primary Care
Number of subjects: 66
Study 23947143 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaihu Shugan San
Number of subjects: 0
Study 23947143 — intervention group
Group type: COMPARATOR
Intervention: Model control group
Number of subjects: 0
Study 21475078 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW training (standard exercise and RENEW)
Number of subjects: 19
Study 21475078 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise (STAND)
Number of subjects: 19
Study 19300232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapro lightweight mesh in the sublay position
Number of subjects: 54
Study 19300232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mesh)
Number of subjects: 54
Study 17594732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vasodilators
Number of subjects: 0
Study 15083940 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg)
Number of subjects: 10
Study 15083940 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (2 mg)
Number of subjects: 10
Study 15083940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11475343 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin-containing solution
Number of subjects: 21
Study 9727896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus metformin
Number of subjects: 18
Study 9727896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9581674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided liver biopsy
Number of subjects: 0
Study 9581674 — intervention group
Group type: COMPARATOR
Intervention: Blind percutaneous liver biopsy
Number of subjects: 0
Study 2153334 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate infusion (2.5 mmol/min)
Number of subjects: 15
Study 2153334 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate infusion (2.5 mmol/min) with glucose (20 g/m2 body surface area)
Number of subjects: 15
Study 2153334 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate infusion (2.8 mmol/min)
Number of subjects: 15
Study 273932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash formulations (specific formulations not detailed)
Number of subjects: 66
Study 273932 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent examinations of the six selected teeth
Number of subjects: 66
Study 273932 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial scores
Number of subjects: 66
Study 31366875 — intervention group
Group type: EXPERIMENTAL
Intervention: β-CRX-rich orange juice (125 mL, after breakfast)
Number of subjects: 23
Study 31366875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (β-CRX removed from orange juice, 125 mL, after breakfast)
Number of subjects: 23
Study 28114921 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidification group (high flow CO2 warming system with standard care)
Number of subjects: 22
Study 28114921 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care alone)
Number of subjects: 22
Study 28114921 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidification group
Number of subjects: 22
Study 28114921 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 25765784 — intervention group
Group type: EXPERIMENTAL
Intervention: Four mini-implants (GI)
Number of subjects: 120
Study 25765784 — intervention group
Group type: EXPERIMENTAL
Intervention: Two mini-implants (GII)
Number of subjects: 120
Study 25765784 — intervention group
Group type: EXPERIMENTAL
Intervention: Two standard implants (GIII)
Number of subjects: 120
Study 23866802 — intervention group
Group type: EXPERIMENTAL
Intervention: External pleural suction (‐15 cmH2O, group A)
Number of subjects: 500
Study 23866802 — intervention group
Group type: COMPARATOR
Intervention: No external suction (control arm, group B)
Number of subjects: 500
Study 23866802 — intervention group
Group type: EXPERIMENTAL
Intervention: External pleural suction (‐15 cmH2O, group A) in anatomic resection subgroup
Number of subjects: 500
Study 23866802 — intervention group
Group type: COMPARATOR
Intervention: No external suction (control arm, group B) in anatomic resection subgroup
Number of subjects: 500
Study 21696308 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR48 group (telaprevir for 12 weeks and peginterferon plus ribavirin for 48 weeks)
Number of subjects: 663
Study 21696308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in T12PR48 group (4 weeks of peginterferon plus ribavirin followed by 12 weeks of telaprevir and peginterferon plus ribavirin for 48 weeks)
Number of subjects: 663
Study 21696308 — intervention group
Group type: COMPARATOR
Intervention: Control group (PR48, peginterferon plus ribavirin for 48 weeks)
Number of subjects: 663
Study 21696308 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR48 group
Number of subjects: 663
Study 21696308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in T12PR48 group
Number of subjects: 663
Study 21696308 — intervention group
Group type: COMPARATOR
Intervention: Control group (PR48)
Number of subjects: 663
Study 21696308 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir groups
Number of subjects: 663
Study 19388860 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with cherry-flavored scent in oxygen (4 L/min)
Number of subjects: 284
Study 19388860 — intervention group
Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 284
Study 17531627 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonographers
Number of subjects: 117
Study 17531627 — intervention group
Group type: COMPARATOR
Intervention: Cytotechnologist
Number of subjects: 117
Study 15156937 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient educational program
Number of subjects: 56
Study 15156937 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 11801811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral piracetam
Number of subjects: 5
Study 11801811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9721974 — intervention group
Group type: EXPERIMENTAL
Intervention: AT III supplementation
Number of subjects: 29
Study 9721974 — intervention group
Group type: COMPARATOR
Intervention: Conventional intensive care treatment
Number of subjects: 29
Study 8306739 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial lung‐expanding compound (ALEC, 3.2 g via bronchoscope)
Number of subjects: 16
Study 8306739 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 16
Study 2451135 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concomitant bleomycin (RT-BLM)
Number of subjects: 199
Study 2451135 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 199
Study 29624543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 45
Study 29624543 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 45
Study 28290093 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH supplementation with rFSH
Number of subjects: 0
Study 28290093 — intervention group
Group type: COMPARATOR
Intervention: rFSH only (Control)
Number of subjects: 0
Study 28290093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 26153496 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib
Number of subjects: 307
Study 26153496 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo
Number of subjects: 307
Study 23290818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia
Number of subjects: 200
Study 23290818 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cognitive psychiatric disorders
Number of subjects: 200
Study 23290818 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff recognition of persistent dementias
Number of subjects: 200
Study 23290818 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for persistent dementia cases
Number of subjects: 200
Study 23290818 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for persistent non-cognitive psychiatric disorder cases
Number of subjects: 200
Study 21686215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dialysis (6 days/nights of dialysis)
Number of subjects: 0
Study 21686215 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysis
Number of subjects: 0
Study 19774773 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 10
Study 19774773 — intervention group
Group type: COMPARATOR
Intervention: No mouthpiece (Control)
Number of subjects: 10
Study 16728295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (4-week duration)
Number of subjects: 30
Study 16728295 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 30
Study 14729296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes patient education interventions
Number of subjects: 2439
Study 14729296 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face delivery, cognitive reframing teaching method, and exercise content
Number of subjects: 2439
Study 11513780 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (intervention): excised 3 x 2 cm gastric crescent from the anterior wall of the gastric tube before constructing the cervical esophagogastric anastomosis.
Number of subjects: 100
Study 11513780 — intervention group
Group type: COMPARATOR
Intervention: Group B (control): no intervention.
Number of subjects: 100
Study 9068434 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic arnica C30
Number of subjects: 73
Study 9068434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8262872 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (500 + 500 mg qds)
Number of subjects: 104
Study 8262872 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam (600 tds) and Clindamycin (1000 mg tds)
Number of subjects: 104
Study 4037642 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal morphine 10 mg in saline 25 ml injected into the caudal epidural space at the end of surgery
Number of subjects: 33
Study 4037642 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg on request in the postoperative period
Number of subjects: 33
Study 4037642 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal morphine 10 mg
Number of subjects: 33
Study 4037642 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 33
Study 30673030 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless jet injection system
Number of subjects: 41
Study 30673030 — intervention group
Group type: COMPARATOR
Intervention: Carpule syringe
Number of subjects: 41
Study 30673030 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional method of anesthesia
Number of subjects: 41
Study 28992580 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to Ray's Night Out app
Number of subjects: 197
Study 28992580 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to Ray's Night Out app
Number of subjects: 197
Study 28992580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Immediate and Delayed access)
Number of subjects: 197
Study 28992580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ray's Night Out app
Number of subjects: 197
Study 27276234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of 110 to 139 mm Hg)
Number of subjects: 1000
Study 27276234 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of 140 to 179 mm Hg)
Number of subjects: 1000
Study 27276234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1000
Study 27276234 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1000
Study 24616593 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (n=20)
Number of subjects: 39
Study 24616593 — intervention group
Group type: COMPARATOR
Intervention: Control (n=19)
Number of subjects: 39
Study 22753922 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg plus carboplatin/paclitaxel
Number of subjects: 1090
Study 22753922 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel alone (placebo)
Number of subjects: 1090
Study 20003585 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil 5 percent cream, three successive applications with two-week intervals
Number of subjects: 60
Study 20003585 — intervention group
Group type: COMPARATOR
Intervention: Local petroleum jelly cream packing
Number of subjects: 60
Study 20003585 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil 5 percent cream
Number of subjects: 60
Study 17068214 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine capsules (dose = 4 mg/kg)
Number of subjects: 14
Study 17068214 — intervention group
Group type: COMPARATOR
Intervention: Gelatin (placebo)
Number of subjects: 14
Study 15856068 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfat with phytosterols (NFPS)
Number of subjects: 15
Study 15856068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat with phytosterols (LFPS)
Number of subjects: 15
Study 15856068 — intervention group
Group type: COMPARATOR
Intervention: Nonfat placebo (NF control)
Number of subjects: 15
Study 12469007 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 24
Study 12469007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9595967 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (100 to 180 mg loading dose for 2 weeks, followed by 30 to 60 mg maintenance dose for 24 weeks)
Number of subjects: 408
Study 9595967 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 408
Study 9595967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 8572867 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment for 3 months
Number of subjects: 6530
Study 8572867 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methods to define a responder
Number of subjects: 6530
Study 8572867 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effect and regression to the mean
Number of subjects: 6530
Study 8572867 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BP level for inclusion
Number of subjects: 6530
Study 8572867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oldham's method for adjusting for regression to the mean
Number of subjects: 6530
Study 2705806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (n = 17)
Number of subjects: 38
Study 2705806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 38
Study 322009 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 68
Study 322009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31237722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of pelvic floor muscle contraction using 2D levator hiatal AP diameter
Number of subjects: 195
Study 31237722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of pelvic floor muscle contraction using 3D levator hiatal AP diameter
Number of subjects: 195
Study 31237722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of pelvic floor muscle contraction using hiatal area
Number of subjects: 195
Study 31237722 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ultrasound measurements and MOS score
Number of subjects: 195
Study 31237722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound contraction scale
Number of subjects: 195
Study 31237722 — intervention group
Group type: EXPERIMENTAL
Intervention: Major levator injury assessment using tomographic ultrasound
Number of subjects: 195
Study 29032175 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60mg
Number of subjects: 53
Study 29032175 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120mg
Number of subjects: 53
Study 29032175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 27120294 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsymptom exacerbation aerobic training
Number of subjects: 30
Study 27120294 — intervention group
Group type: COMPARATOR
Intervention: Full-body stretching program
Number of subjects: 30
Study 25534375 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-plus-taxane combination with carboplatin (PMCb)
Number of subjects: 580
Study 25534375 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-plus-taxane combination (PM)
Number of subjects: 580
Study 25534375 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of stromal TILs
Number of subjects: 580
Study 25534375 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression of immune markers (12 immune mRNA markers)
Number of subjects: 580
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologists with higher false-positive rates (FPRs) (FPR > 27.1%)
Number of subjects: 112
Study 23592767 — intervention group
Group type: COMPARATOR
Intervention: Radiologists with lower false-positive rates (FPRs) (FPR ≤ 27.1%)
Number of subjects: 112
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean FPR for radiologists
Number of subjects: 112
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairs of radiologists within the same screening center
Number of subjects: 112
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairs of radiologists across all centers
Number of subjects: 112
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic centers
Number of subjects: 112
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacademic centers
Number of subjects: 112
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers inside the U.S. 'histoplasmosis belt'
Number of subjects: 112
Study 23592767 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers outside the U.S. 'histoplasmosis belt'
Number of subjects: 112
Study 21878677 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d)
Number of subjects: 27447
Study 21878677 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen alone
Number of subjects: 27447
Study 21878677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27447
Study 19190070 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast providing 125 microg folate (breakfast group; n = 17)
Number of subjects: 51
Study 19190070 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 slices of whole‐meal bread providing 70 microg folate (bread group; n = 17)
Number of subjects: 51
Study 19190070 — intervention group
Group type: COMPARATOR
Intervention: Apple juice (control group; n = 17)
Number of subjects: 51
Study 17097811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg alprazolam
Number of subjects: 46
Study 17097811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15504189 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 8 mg
Number of subjects: 10